In ER+ early-stage breast cancer

The only robust, validated tool to help with clinical decision-making for extended endocrine treatment

  • Predictive for likelihood of benefit from extended endocrine therapy
  • Prognostic for risk of late distant recurrence

ORDER A TEST

Actionable genomic information for accurate diagnosis for metastatic patients with diagnostic ambiguity

  • CancerTYPE ID is a most validated gene expression-based assay to help achieve an accurate diagnosis

ORDER A TEST